Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Target Price at $15.57

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been assigned an average rating of “Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have covered the stock in the last year is $15.57.

Several equities research analysts have recently commented on FULC shares. Oppenheimer decreased their target price on shares of Fulcrum Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Tuesday, May 14th. HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Fulcrum Therapeutics in a report on Thursday, August 1st. The Goldman Sachs Group raised Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $6.00 to $15.00 in a research note on Monday, May 13th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $23.00 target price on shares of Fulcrum Therapeutics in a report on Wednesday, July 10th.

Fulcrum Therapeutics Trading Down 4.6 %

Shares of FULC stock opened at $9.24 on Monday. The firm has a fifty day simple moving average of $7.77 and a two-hundred day simple moving average of $8.37. Fulcrum Therapeutics has a 12 month low of $3.14 and a 12 month high of $13.70. The firm has a market capitalization of $574.30 million, a PE ratio of -5.78 and a beta of 2.29.

Hedge Funds Weigh In On Fulcrum Therapeutics

Several institutional investors have recently modified their holdings of the business. National Bank of Canada FI boosted its position in Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock worth $28,000 after purchasing an additional 4,000 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Fulcrum Therapeutics by 66.7% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,916 shares of the company’s stock worth $112,000 after purchasing an additional 4,766 shares during the period. Capstone Investment Advisors LLC purchased a new position in shares of Fulcrum Therapeutics in the 4th quarter worth about $68,000. Profund Advisors LLC bought a new position in Fulcrum Therapeutics during the second quarter valued at about $68,000. Finally, American Century Companies Inc. increased its holdings in Fulcrum Therapeutics by 13.2% during the second quarter. American Century Companies Inc. now owns 104,371 shares of the company’s stock worth $647,000 after buying an additional 12,167 shares during the last quarter. 89.83% of the stock is owned by institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.